Attributable mortality of nosocomial candidemia, revisited.

By Ó. Gudlaugsson, Shane M. Gillespie, Kathleen Lee, J. Vande Berg, Jianfang Hu, S. Messer, L. Herwaldt, M. Pfaller, D. Diekema. Clinical Infectious Diseases, 2003

1,182 citations recorded by the source corpus.

Subfields: Clinical Biochemistry, Endocrinology, Oncology

View Paper: https://www.semanticscholar.org/paper/2123dfb48cf23048080a5d48cf5c496379135911

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Clinical Biochemistry

1. J. Fishman
2. M. Pfaller
3. D. Diekema

In Endocrinology

1. Gordon D. Brown

In Oncology

1. J. Fishman

Citations in the corpus

• Real-Time PCR in Clinical Microbiology: Applications for Routine Laboratory Testing (2006, background): “Candida species are the fourth leading cause of nosocomial bloodstream infections and are associated with a mortality rate of 40 to 50% so rapid and reliable detection of candidemia has attracted significant interest (105, 152, 366).”
• An integrated model of the recognition of Candida albicans by the innate immune system (2008, background): “1 and 24 cases per 100,000 individuals, and an associated mortality of more than 30”
• Epidemiology of Invasive Mycoses in North America (2010, background): “…to candidemia and other forms of invasive candidiasis have been reported from retrospective matched-cohort studies conducted in single institutions (Gudlaugsson et al. 2003; Pelz et al. 2000; Puzniak et al. 2006; Wey et al. 1988) and in the context of population surveillance studies (Table 13)…”
• Genomics of the fungal kingdom: Insights into eukaryotic biology (2005, background): “The two most common fungal pathogens are Candida and Aspergillus species: Candidiasis is the most common HIV-related fungal infection with mortality reaching 49% (Gudlaugsson et al. 2003) while Aspergillosis has caused up to 10,000 hospitalizations per year with mortality as high as 20% (Dasbach et ”
• Incidence of Bloodstream Infections Due to Candida Species and In Vitro Susceptibilities of Isolates Collected from 1998 to 2000 in a Population-Based Active Surveillance Program (2004, background): “These infections are associated with attributable mortality rates that have ranged from 38% between 1983 and 1986 (46) to 49% in the same institutions between 1997 and 2001 (13).”
• Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. (2009, background): “Attributable mortality has been reported to range from 5% to 71%, and crude mortality rates have been reported to be as high as 81% [11–23].”
• Candida parapsilosis, an Emerging Fungal Pathogen (2008, background): “parapsilosis fungemia can lead to seeding of tissues, resulting in deep-seated infections (103), and has a mortality rate ranging from 4% (142) to 45% (34, 52, 108).”
• The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. (2005, background): “In adult patients, the rate of mortality attributable to candidemia has ranged from 38% to 49% [10, 11], with a published case-fatality rate as high as 61% [ 11 ].”
• Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America (2009, background): “Invasive candidiasis has a significant impact on patient outcomes, and it has been estimated that the attributable mortality of invasive candidiasis is as high as 47% [11], although many authorities estimate the attributable mortality to be 15%–25% for adults and 10%–15% for neonates and children [1”
• Global trends in the distribution of Candida species causing candidemia. (2014, background): “Candidemia has an attributable mortality of 15–35% for adults and 10–15% for neonates, and the hospitalization cost for each episode is approximately US$40 000 [11–13].”
• Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. (2006, background): “Attributable mortality rates of 49% were also shown among patients with candidemia, compared with uninfected control subjects matched for age, sex, date of hospital admission, underlying diseases, length of time at risk, and type of surgical procedure [5].”
• Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. (2007, background): “The attributable mortality associated with candidemia may be as high as 47% [7, 8], although it is estimated to be 15%–25% for adults and 10%–15% for”
• Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “to 47% attributable mortality [5–13], and this is even higher among persons with septic shock [14].”
• Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007, background): “In order to better estimate the contribution of the infectious process to mortality, LOS, and costs of care, one must conduct matched-cohort studies where the case patients are carefully matched to control subjects for all variables except for the candidal infections (59, 89, 164, 195, 238, 307, 308”
• Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. (2012, background): “Mortality rates associated with invasive candidiasis (IC) approach 50% [6–13].”